TileDB Powers Multiomics Research: Now Trusted by Half of Top Global Pharma Giants

TileDB, a database designed for scientific discovery, is now used by 50% of the top 20 global pharmaceutical companies, including Boehringer Ingelheim, highlighting its crucial role in advancing precision medicine through drug discovery pipelines reliant on multimodal, multiomics data. In addition to its growing adoption, TileDB is expanding its leadership team with strategic appointments to enhance its market reach and support its status as a preferred foundation for scientific breakthroughs. The company opened a new office in New York City and welcomed new board members, including George Llado, a former CIO with extensive biopharmaceutical experience, and Jeff Miller, a seasoned revenue officer. These appointments aim to leverage TileDB's innovative approach to data analysis, enabling researchers to tackle complex, multidimensional data in fields such as single-cell, proteomics, and population genomics, thereby accelerating drug discovery and potentially advancing treatments for rare and hard-to-treat diseases.